173 related articles for article (PubMed ID: 26252303)
1. Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography for Follow-Up of 13-cis-Retinoic Acid Treatment for Residual Neuroblastoma After Myeloablative Chemotherapy.
Sato Y; Kurosawa H; Sakamoto S; Kuwashima S; Hashimoto T; Okamoto K; Tsuchioka T; Fukushima K; Arisaka O
Medicine (Baltimore); 2015 Aug; 94(31):e1290. PubMed ID: 26252303
[TBL] [Abstract][Full Text] [Related]
2. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
Sharp SE; Shulkin BL; Gelfand MJ; Salisbury S; Furman WL
J Nucl Med; 2009 Aug; 50(8):1237-43. PubMed ID: 19617326
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
[TBL] [Abstract][Full Text] [Related]
4. Monitoring isotretinoin therapy in thyroid cancer using 18F-FDG PET.
Boerner AR; Petrich T; Weckesser E; Fricke H; Hofmann M; Otto D; Weckesser M; Langen KJ; Knapp WH
Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):231-6. PubMed ID: 11926385
[TBL] [Abstract][Full Text] [Related]
5. ¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma.
Melzer HI; Coppenrath E; Schmid I; Albert MH; von Schweinitz D; Tudball C; Bartenstein P; Pfluger T
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1648-58. PubMed ID: 21617976
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
[TBL] [Abstract][Full Text] [Related]
7. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma.
Taggart DR; Han MM; Quach A; Groshen S; Ye W; Villablanca JG; Jackson HA; Mari Aparici C; Carlson D; Maris J; Hawkins R; Matthay KK
J Clin Oncol; 2009 Nov; 27(32):5343-9. PubMed ID: 19805691
[TBL] [Abstract][Full Text] [Related]
8. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
[TBL] [Abstract][Full Text] [Related]
9. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative.
Colavolpe C; Guedj E; Cammilleri S; Taïeb D; Mundler O; Coze C
Pediatr Blood Cancer; 2008 Dec; 51(6):828-31. PubMed ID: 18680162
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
11. (18)F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy.
Choi YJ; Hwang HS; Kim HJ; Jeong YH; Cho A; Lee JH; Yun M; Lee JD; Kang WJ
Ann Nucl Med; 2014 May; 28(4):304-13. PubMed ID: 24481823
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of high-risk neuroblastoma with intensive chemotherapy, autologous peripheral blood stem cell transplantation, and 13-cis-retinoic acid].
Tang SQ; Huang DS; Wang JW; Zhang XF; Liu LZ; Yu F; Yang G
Zhonghua Er Ke Za Zhi; 2004 Jul; 42(7):486-9. PubMed ID: 15324562
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with (18)F-fluorodeoxyglucose positron emission tomography and (123)I-metaiodobenzylguanine scintigraphy in pediatric neuroblastoma: complementary roles in follow-up of patients.
Gil TY; Lee DK; Lee JM; Yoo ES; Ryu KH
Korean J Pediatr; 2014 Jun; 57(6):278-86. PubMed ID: 25076973
[TBL] [Abstract][Full Text] [Related]
14. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy.
Shulkin BL; Hutchinson RJ; Castle VP; Yanik GA; Shapiro B; Sisson JC
Radiology; 1996 Jun; 199(3):743-50. PubMed ID: 8637999
[TBL] [Abstract][Full Text] [Related]
15. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
[TBL] [Abstract][Full Text] [Related]
16. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative.
Mc Dowell H; Losty P; Barnes N; Kokai G
Pediatr Blood Cancer; 2009 Apr; 52(4):552. PubMed ID: 19058210
[No Abstract] [Full Text] [Related]
17. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
18. Weak uptake of 123I-MIBG and 18F-FDOPA contrasting with high 18F-FDG uptake in stage I neuroblastoma.
Wartski M; Jehanno N; Michon J; de Labriolle-Vaylet C; Montravers F
Clin Nucl Med; 2015 Dec; 40(12):969-70. PubMed ID: 26544903
[TBL] [Abstract][Full Text] [Related]
19. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
